 EMERYVILLE, Calif., March 09, 2021 GLOBE NEWSWIRE -- 4D Molecular Therapeutics Nasdaq: 4DMT, a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that the first patient has been dosed in the Phase 12 clinical trial of 4D-310 for the treatment of Fabry disease. Fabry disease is an inherited lysosomal storage disease with high unmet medical need that results from loss of function mutations in the alpha-galactosidase AGA enzyme. 